201. Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction: A vehicle-controlled, randomized clinical trial.
- Author
-
Watson SL, Jones LW, Stapleton F, Hinds M, Ng A, Tan J, Alster Y, Bosworth C, Rafaeli O, and DePuy V
- Abstract
Purpose: Meibomian gland dysfunction (MGD) is a chronic progressive disease with downstream effects on ocular signs and symptoms. AZR-MD-001 is a selenium sulfide ophthalmic ointment that was investigated as a potential treatment option for patients with MGD., Methods: A Phase 2, multi-center, double-masked, parallel group study was conducted across 29 sites, with 245 patients randomized 1:1:1 to AZR-MD-001 0.5%, AZR-MD-001 1.0% or vehicle applied to the lower eyelid, twice weekly. Patients were eligible for the trial if they presented with signs and symptoms of MGD. Co-primary efficacy endpoints were the changes from baseline in number of open glands (Meibomian Glands Yielding Liquid Secretion [MGYLS] score) and patient-reported ocular surface symptoms (Ocular Surface Disease Index [OSDI] total score) at Month 3. Efficacy outcomes were captured at Day 14, Month 1.5 and Month 3. Safety and tolerability were assessed for treatment-emergent adverse events (TEAEs)., Results: AZR-MD-001 0.5% (n = 82 patients) treatment resulted in significant improvements in MGYLS score, with patients experiencing an average increase from baseline of 4.2 and 2.4 open glands secreting meibum for the drug and vehicle, respectively (p < 0.001) and from baseline a mean OSDI total score improvement of 7.3 and 3.8 for the drug and vehicle, respectively (p < 0.05). Most TEAEs were mild and transient, with 3 serious adverse events (SAEs) reported with AZR-MD-001 (none related to study drug)., Conclusions: Co-primary endpoints were met for AZR-MD-001 0.5% at Month 3, with a statistically significant improvement in the signs and symptoms of MGD. AZR-MD-001 was safe and well tolerated., Trial Registration: ClinicalTrials.gov Identifier: NCT03652051, ANZCTR Registration Number: AZ201801., Competing Interests: Declaration of competing interest Stephanie Watson (ORCID ID: 0000-0001-6699-1765): Within the past 3 years, SW has received grant support, allocated to her research group, from Seqirus; has participated on an advisory board for Alcon Global; and has received honoraria for lectures or speakers bureaus from Novartis and Seqirus. SW also serves as a Chair of Australian Vision Research and is an inventor on US Patent US20200281924. Lyndon W. Jones (ORCID ID: 0000-0002-7409-7349): Within the past 3 years, LWJ has received research support or lectureship honoraria from the following companies, allocated to the Centre for Ocular Research and Education (CORE): Alcon, Azura Ophthalmics, Bausch Health, CooperVision, Essilor, Hoya, i-Med Pharma, J&J Vision, Menicon, Novartis, Ophtecs, Oté Pharma, Santen, SightGlass, SightSage, Topcon and Visioneering. LWJ is also a consultant and/or serves on an advisory board for Alcon, CooperVision, J&J Vision, Novartis and Ophtecs. Fiona Stapleton: Within the past 3 years, FS has received research support from the following companies: Alcon, Azura Ophthalmics, Exonate, Kedalion Therapeutics, Menicon, Novartis and Nthalmics. FS has also been a consultant for CooperVision and has participated on advisory boards for Alcon, Seqirus, and Novartis. FS is the immediate past-president of the International Society for Contact Lens Research and is a steering committee member and subcommittee chair of Tear Film and Ocular Surface Society, Lifestyle Epidemic Workshop. Mark Hinds: MH has received research funding and/or honoraria from Vyluma, Kiora Pharmaceuticals, SynergEyes, CORE Research Group (Eli Lilly and Company), Novo Nordisk, Alcon and the Queensland University of Technology (School of Optometry and Vision Science). He has provided expert testimony for Remedy Medicolegal, Avant Insurance and Murphey's Law. MH is also a consultant for and/or serves on an advisory board for Kiora Pharmaceuticals and the Dry Eye Society. Alison Ng (ORCID ID: 0000-0002-6277-8470): AN is an employee of the Centre for Ocular Research and Education (CORE). Within the past 3 years, her institution has received research funding and/or honoraria from the 17 companies and 7 funding agencies listed: Alcon, Azura Ophthalmics, Bausch + Lomb Corp, CooperVision, Essilor, Hoya, I-MED Pharma, Johnson & Johnson Vision, Menicon, Novartis, Ophtecs, Oté Pharma, Santen, SightGlass, SightSage, Topcon, Visioneering Tech Inc, NSERC, CIHR, Mitacs, Canadian Association of Optometrists, European Commission Horizon 2020, Canada Foundation for Innovation, Innovation and Technology Commission (Government of the Hong Kong Special Administrative Region of the People's Republic of China). Jacqueline Tan (ORCID ID: 0000-0003-4986-4945): Within the past 3 years, JT has received research funding (paid to institution) from Alcon, Azura Ophthalmics, Exonate, Kedalion Therapeutics, Novartis, nthalmic and Rodenstock; has received support for attending International Society for Contact Lens Research and Tear Film and Ocular Society; has participated on an advisory board for Azura Ophthalmics; and has received non-monetary support (e.g., equipment, materials, other services) from Melcare and OptiMed. Yair Alster: YA is an inventor on patents related to AZR-MD-001 and is an employee of and has stock and options in Azura Ophthalmics. Charles Bosworth: CB is an employee of Azura Ophthalmics. Omer Rafaeli: OR is an employee of Azura Ophthalmics. Venita DePuy: VD is a statistical consultant to Azura Ophthalmics., (Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF